Pfizer, in collaboration with German mRNA company BioNTech, has already begun the clinical trials for the BNT162 vaccine program in the U.S. and Europe to prevent the effect of the virus to the maximum possible extent.Original Article
You may also like
Insurers Hedge on Trump-Backed Pledge To Improve...
Violence Repeatedly Erupts at Dementia Care Facilities...
Doctors ‘Cringe’ at Possibility of Documenting...
Pregnant Woman’s Roadside Death Triggers Push To...
Tempus to buy cancer test-maker Personalis for $1.5B
Resmed ventilator safety issue linked to 5 serious...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
